POSTER PRESENTATION

Open Access

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)

Charu Singh

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

Aim

To evaluate the efficacy, toxicity, overall survival and response of Gefitinib in previously untreated patients of metastatic NSCLC with EGFR mutation.

Methods

60 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy were randomly assigned to receive Gefitinib 250 mg orally daily or carboplatin -paclitaxel. The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.

Results

The progression free survival was significantly longer in Gefitinib group than in standard chemotherapy group. The Gefitinib group had significantly longer median progression free survival (10 months versus 5 months) as well as higher response rates (70% versus 30%). The median overall survival was 30 months in Gefitinib group and 24 months in chemotherapy group. The most common adverse events in Gefitinib group were rash and elevated aminotransferase levels.

Conclusions

First-line Gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.

doi:10.1186/2051-1426-2-S3-P187

Cite this article as: Singh: Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P187.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

Published: 6 November 2014

S.M.S Medical College and Hospital, JAIPUR, India

© 2014 Singh; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.